- Life Science
- Flow cytometry
- Digital pathology
- QC & Online Services
- Document Centre
- Knowledge Centre
- Clinic & Laboratory
Select your local website
How can non-palpable lesions in early-stage cancer patients be accurately targeted and removed?
Non-palpable lesions never have to be removed
The lesion can be marked with Magseed® magnetic markers and localised with the Sentimag® probe
Upon incision, the lesion can be identified visually without further support
That's the correct answer!
Please try again
Please try again
Please select at least one answer
Due to improvements in screening and patient awareness, approximately 50% of breast lesions are impalpable at the time of diagnosis. The current gold standard to assist the surgeon in finding an impalpable lesion is a hook wire, or guidewire. These are usually placed on the morning of surgery. Wire-guided localisations (WGL) have been used since the 1960s and have several limitations, including migration of the wire, scheduling conflicts and patient dissatisfaction.
Magseed® has been specifically developed to overcome these issues. It promotes seamless operating room (OR) scheduling, highly accurate lesion localisation and high patient satisfaction.
Our system consists of the Sentimag® probe and the Magseed® magnetic marker. Before surgery, the marker is deployed under ultrasound or X-ray guidance. It is firmly implanted without any parts protruding from the skin, thereby improving comfort for the patient and minimising migration and infection risk. In the OR, the surgeon uses Sentimag® to precisely localise the Magseed® and therefore the tumour.
Singh P et al. (2019). Ann. Surg. Oncol. 26(suppl. 1): S74-5.
Lamb LR et al. (2018). Am J Roentgenol. 211,4: 940-5.
Harvey et al. (2018). Breast Cancer Res Treat- 169(3):531-6
Price et al. (2018). Am J Roentgenol. 210(4):913-7.
Smeets A et al. (2018). Europ. J Cancer 92 (suppl. 3): S73.
Endomag®, Sentimag® and Magseed® are registered European Union trade marks of Endomagnetics Ltd. www.endomag.com